Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Research & Development: 2013-2025

Historic Research & Development for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $22.4 million.

  • Amphastar Pharmaceuticals' Research & Development rose 6.06% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.7 million, marking a year-over-year increase of 5.88%. This contributed to the annual value of $73.9 million for FY2024, which is 0.23% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Research & Development is $22.4 million, which was up 11.32% from $20.1 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Research & Development peaked at $22.8 million during Q2 2022, and registered a low of $10.8 million during Q3 2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Research & Development value was $19.8 million (recorded in 2023), while the average stood at $19.1 million.
  • Its Research & Development has fluctuated over the past 5 years, first plummeted by 39.02% in 2021, then skyrocketed by 72.08% in 2022.
  • Amphastar Pharmaceuticals' Research & Development (Quarterly) stood at $17.3 million in 2021, then decreased by 0.29% to $17.2 million in 2022, then climbed by 18.47% to $20.4 million in 2023, then fell by 11.15% to $18.1 million in 2024, then grew by 6.06% to $22.4 million in 2025.
  • Its last three reported values are $22.4 million in Q3 2025, $20.1 million for Q2 2025, and $20.1 million during Q1 2025.